<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thrombin-activatable fibrinolysis inhibitor (TAFI) is a plasma carboxypeptidase that renders a fibrin-containing <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> less sensitive to lysis </plain></SENT>
<SENT sid="1" pm="."><plain>Since the role of TAFI in <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation is still controversial in mice, our present study was designed to evaluate mice deficient in TAFI (TAFI(-/-)) on FeCl(3)-induced vena cava and carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Parallel studies were carried out in <z:mp ids='MP_0002169'>wild-type</z:mp> mice using a potato carboxypeptidase inhibitor (PCI), a selective inhibitor of activated TAFI (TAFIa) </plain></SENT>
<SENT sid="3" pm="."><plain>Significant reduction in <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation was observed in TAFI(-/-) mice (n = 8, P &lt; 0.05 compared to <z:mp ids='MP_0002169'>wild-type</z:mp> littermates) but not in heterozygous (TAFI(+/-)) mice in 3.5% FeCl(3)-induced vena cava <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>A similar effect was observed following treatment with 5 mg/kg bolus plus 5 mg/kg/h PCI in the same <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> model in C57BL/6 mice (n = 8, P &lt; 0.01 compared to vehicle) </plain></SENT>
<SENT sid="5" pm="."><plain>No compositional difference was observed for the venous <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in TAFI(-/-) and <z:mp ids='MP_0002169'>wild-type</z:mp> littermates with or without PCI treatment using histological assessment </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, neither TAFI deficiency nor treatment with PCI showed antithrombotic efficacy in the 3.5% FeCl(3)-induced carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> model </plain></SENT>
<SENT sid="7" pm="."><plain>In a tail transection <z:mp ids='MP_0001914'>bleeding</z:mp> time model, both TAFI deficiency and PCI treatment <z:hpo ids='HP_0003010'>increased bleeding time</z:hpo> up to 4.5 and 3.5 times, respectively, over controls (P &lt; 0.05, n = 8) </plain></SENT>
<SENT sid="8" pm="."><plain>Similar ex vivo fibrinolytic activities were demonstrated for both TAFI deficiency and PCI treatment as enhanced lysis of thrombin-induced plasma clots and lysis of whole blood clot in a thrombelastograph </plain></SENT>
<SENT sid="9" pm="."><plain>These data provide direct evidence for the role of TAFIa in vena cava <z:mp ids='MP_0005048'>thrombosis</z:mp> without the addition of exogenous thrombolytic in mice </plain></SENT>
<SENT sid="10" pm="."><plain>The strong ex vivo fibrinolytic activity of TAFI deficiency or TAFIa inhibition by PCI provides a biomarker of TAFIa inhibition that tracks in vivo antithrombotic efficacy </plain></SENT>
</text></document>